AR005245A1 - Prodrogas de inhibidores de trombina, una formulación farmaceutica que las comprende, el uso de dichas prodrogas para la manufactura de un medicamento y un procedimiento para su preparacion - Google Patents

Prodrogas de inhibidores de trombina, una formulación farmaceutica que las comprende, el uso de dichas prodrogas para la manufactura de un medicamento y un procedimiento para su preparacion

Info

Publication number
AR005245A1
AR005245A1 ARP960105567A ARP960105567A AR005245A1 AR 005245 A1 AR005245 A1 AR 005245A1 AR P960105567 A ARP960105567 A AR P960105567A AR P960105567 A ARP960105567 A AR P960105567A AR 005245 A1 AR005245 A1 AR 005245A1
Authority
AR
Argentina
Prior art keywords
alkyl
halogen
optionally substituted
prodroges
naphthyl
Prior art date
Application number
ARP960105567A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9526273A external-priority patent/GB9526273D0/en
Priority claimed from SE9600556A external-priority patent/SE9600556D0/xx
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR005245A1 publication Critical patent/AR005245A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/022—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2
    • C07K5/0222—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2 with the first amino acid being heterocyclic, e.g. Pro, Trp
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Prodrogas de inhibidores de trombina, que comprenden la fórmula (I): RaOCC-CH2-(R)Cgl-Aze-Pab-Hdonde R1 es -R3 o -A1C(O)N(R4)R5 o -A1C(O)(R4); A1 es alquileno de C1-5; R2 (que reemplaza uno de los átomos de hidrógeno en la unidad amidino d e Pab- H esOH, OC(O)R6,C(O)OR7 o C(O)OCH(R8)OC(O)R9; R3 es H, alquilo C1-10, o alquilfenilo C1-3 (estando este último grupo opcionalmente substituido conalquilo C1-6, alcoxi C1-6, nitro o halógeno); R4-R5 son independientemente H, alquil o C1-6, fenilo, 2- naftilo o, cuando R1 es A1C(O)N(R4)R5, conjuntamentecon el átomo de nitrógeno al cual están unidos son pirrolidinilo o piperidinilo; R6 es alquilo C1-17, fenilo o 2-naftilo (todos los cuales estánopcionalmente substitui dos con alquilo C1-6, alcoxiC1-6, nitro o halógeno); R7 es 2-naftilo, fenilo, alquilfenilo C1-3 (cuyos últimos tres grupos estánopcionalmente substituidos con alquilo C1-6, alcoxi C1-6, nitro o halógeno)o alquilo C1-12 (cuyo último grupo está opc ionalmente substituido conalcoxiC1-6, aciloxi C1-6 o halógeno); R8 es H o alquilo C1-4; y R9 es 2-naftilo, fenilo, alcoxi C1-6 o alquilo C1-8 (cuyo último grupo está opcionalmentesubstituido con halógeno, alcoxi C1-6 o aciloxi C1-6); con la con dición de que cuando R1 esR3; R3 es bencilo, metilo, etilo, n-butilo o n-hexilo y R2 esC(O)OR7, entonces R7 no es bencilo; o una sal farmacéuticamente aceptable del mismo; donde Cgl es ciclohexilglicina; Aze significa ácido S-azetidina-2-carboxíl ico y Pab significa unradical bivalente derivado de 1-amidino-4- aminometilbenceno; una formulación farmacéutica que los comprende, el uso dedichas drogas para la manufactura de un medicamento y un procedimiento para su preparación.
ARP960105567A 1995-12-21 1996-12-09 Prodrogas de inhibidores de trombina, una formulación farmaceutica que las comprende, el uso de dichas prodrogas para la manufactura de un medicamento y un procedimiento para su preparacion AR005245A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9526273A GB9526273D0 (en) 1995-12-21 1995-12-21 New prodrugs
SE9600556A SE9600556D0 (sv) 1996-02-15 1996-02-15 New prodrugs

Publications (1)

Publication Number Publication Date
AR005245A1 true AR005245A1 (es) 1999-04-28

Family

ID=26308368

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP960105567A AR005245A1 (es) 1995-12-21 1996-12-09 Prodrogas de inhibidores de trombina, una formulación farmaceutica que las comprende, el uso de dichas prodrogas para la manufactura de un medicamento y un procedimiento para su preparacion

Country Status (30)

Country Link
US (4) US5965692A (es)
EP (3) EP0869966B1 (es)
JP (1) JP2000504313A (es)
KR (1) KR100458545B1 (es)
AR (1) AR005245A1 (es)
AT (2) ATE291031T1 (es)
BR (1) BR9612148A (es)
CA (1) CA2238737A1 (es)
DE (3) DE122004000046I2 (es)
DK (2) DK0869966T3 (es)
EE (1) EE04022B1 (es)
ES (2) ES2128283T3 (es)
HK (2) HK1016610A1 (es)
HU (1) HUP9900115A3 (es)
IL (1) IL124857A0 (es)
IS (1) IS1836B (es)
LU (1) LU91172I2 (es)
MX (1) MX9804623A (es)
MY (1) MY121222A (es)
NL (1) NL300179I2 (es)
NO (1) NO982809L (es)
NZ (2) NZ324902A (es)
PL (1) PL187468B1 (es)
PT (1) PT995755E (es)
RU (1) RU2176644C2 (es)
SI (2) SI0995755T1 (es)
SK (1) SK285588B6 (es)
TR (1) TR199801151T2 (es)
TW (2) TW541316B (es)
WO (1) WO1997023499A1 (es)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9301916D0 (sv) * 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
US6984627B1 (en) * 1993-06-03 2006-01-10 Astrazeneca Ab Peptide derivatives
AR005245A1 (es) * 1995-12-21 1999-04-28 Astrazeneca Ab Prodrogas de inhibidores de trombina, una formulación farmaceutica que las comprende, el uso de dichas prodrogas para la manufactura de un medicamento y un procedimiento para su preparacion
SE9602263D0 (sv) 1996-06-07 1996-06-07 Astra Ab New amino acid derivatives
SE9602646D0 (sv) 1996-07-04 1996-07-04 Astra Ab Pharmaceutically-useful compounds
AR013084A1 (es) 1997-06-19 2000-12-13 Astrazeneca Ab Derivados de amidino utiles como inhibidores de la trombina, composicion farmaceutica, utilizacion de dichos compuestos para la preparacion demedicamentos y proceso para la preparacion de los compuestos mencionados
SE9704543D0 (sv) 1997-12-05 1997-12-05 Astra Ab New compounds
IL139162A0 (en) 1998-04-24 2001-11-25 Dimensional Pharm Inc Amidinohydrazone, alkoxyguanidine and aminoguanidine derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
US6274090B1 (en) * 1998-08-05 2001-08-14 Thermogenesis Corp. Apparatus and method of preparation of stable, long term thrombin from plasma and thrombin formed thereby
SE9802938D0 (sv) 1998-09-01 1998-09-01 Astra Ab Improved stability for injection solutions
SE9802974D0 (sv) 1998-09-03 1998-09-03 Astra Ab New crystalline forms
SE9802973D0 (sv) * 1998-09-03 1998-09-03 Astra Ab Immediate release tablet
SE9804313D0 (sv) 1998-12-14 1998-12-14 Astra Ab New compounds
TR200102037T2 (tr) 1999-01-13 2001-10-22 Astrazeneca Ab Yeni amidinobenzilamin türevleri ve trombin engelleyiciler olarak kullanılmaları.
SE9900070D0 (sv) 1999-01-13 1999-01-13 Astra Ab New use
SK14232001A3 (sk) 1999-04-09 2002-06-04 Basf Aktiengesellschaft Nízkomolekulové inhibítory komplementárnych proteáz
CN1355810A (zh) 1999-04-09 2002-06-26 巴斯福股份公司 凝血酶抑制剂的前体药物
AR023510A1 (es) * 1999-04-21 2002-09-04 Astrazeneca Ab Un equipo de partes, formulacion farmaceutica y uso de un inhibidor de trombina.
SE9902550D0 (sv) * 1999-07-02 1999-07-02 Astra Ab New crystalline forms
JP2003504329A (ja) 1999-07-08 2003-02-04 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 抗微生物アミジンの新規プロドラッグ
SE0001803D0 (sv) 2000-05-16 2000-05-16 Astrazeneca Ab New compounds i
US6433186B1 (en) 2000-08-16 2002-08-13 Astrazeneca Ab Amidino derivatives and their use as thormbin inhibitors
US6462021B1 (en) 2000-11-06 2002-10-08 Astrazeneca Ab Use of low molecular weight thrombin inhibitor
AR035216A1 (es) * 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
US7129233B2 (en) 2000-12-01 2006-10-31 Astrazeneca Ab Mandelic acid derivatives and their use as thrombin inhibitors
DE10064797A1 (de) * 2000-12-22 2002-06-27 Knoll Ag Orale und parenterale pharmazeutische Formulierung, umfassend eine niedermolekulare Thrombininhibitor-Pro-Pharmakon
SE0101762D0 (sv) * 2001-05-18 2001-05-18 Astrazeneca Ab New use
SE0101932D0 (sv) * 2001-05-31 2001-05-31 Astrazeneca Ab Pharmaceutical combinations
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
AR034517A1 (es) * 2001-06-21 2004-02-25 Astrazeneca Ab Formulacion farmaceutica
GB0123851D0 (en) * 2001-10-04 2001-11-28 Pankhurst Design & Development Dispersing fragrances
SE0103369D0 (sv) * 2001-10-09 2001-10-09 Astrazeneca Ab Pharmaceutical formulation
SE0103590D0 (sv) 2001-10-26 2001-10-26 Astrazeneca Ab New Combination
SE0200198D0 (sv) 2002-01-23 2002-01-23 Astrazeneca Ab New use
ATE399175T1 (de) 2002-03-11 2008-07-15 Curacyte Ag Hemmstoffe der urokinase, ihre herstellung und verwendung
AU2003221926A1 (en) * 2002-04-10 2003-10-27 Esperion Therapeutics, Inc. Mimics of acyl coenzyme-a comprising pantolactone and pantothenic acid derivatives, compositions thereof, and methods of cholesterol management and related uses
SE0201659D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab Modified release pharmaceutical formulation
SE0201661D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab New salts
DK1569912T3 (en) 2002-12-03 2015-06-29 Pharmacyclics Inc 2- (2-hydroxybiphenyl-3-yl) -1h-benzoimidazole-5-carboxamidine derivatives as factor VIIa inhibitors.
DE10301300B4 (de) 2003-01-15 2009-07-16 Curacyte Chemistry Gmbh Verwendung von acylierten 4-Amidino- und 4-Guanidinobenzylaminen zur Inhibierung von Plasmakallikrein
US7781424B2 (en) * 2003-05-27 2010-08-24 Astrazeneca Ab Modified release pharmaceutical formulation
SE0301879D0 (sv) * 2003-06-25 2003-06-25 Astrazeneca Ab New process
JP4738333B2 (ja) * 2003-07-09 2011-08-03 パラテック ファーマシューティカルズ インコーポレイテッド ９−アミノメチルテトラサイクリン化合物のプロドラッグ
DE10342108A1 (de) 2003-09-11 2005-04-14 Curacyte Chemistry Gmbh Basisch-substituierte Benzylaminanaloga als Inhibitoren des Gerinnungsfaktors Xa, ihre Herstellung und Verwendung
PE20060594A1 (es) * 2004-09-09 2006-08-18 Novartis Ag Composicion farmaceutica que contiene un agonista de ppar
US7524354B2 (en) * 2005-07-07 2009-04-28 Research Foundation Of State University Of New York Controlled synthesis of highly monodispersed gold nanoparticles
DE102006050672A1 (de) 2006-10-24 2008-04-30 Curacyte Discovery Gmbh Hemmstoffe des Plasmins und des Plasmakallikreins
TW200827336A (en) * 2006-12-06 2008-07-01 Astrazeneca Ab New crystalline forms
US20090061000A1 (en) * 2007-08-31 2009-03-05 Astrazeneca Ab Pharmaceutical formulation use 030
DE102009004204A1 (de) * 2009-01-09 2010-07-15 Christian-Albrechts-Universität Zu Kiel Verfahren zur verbesserten Bioaktivierung von Arzneistoffen
DE102009008256A1 (de) 2009-02-10 2010-08-12 Lts Lohmann Therapie-Systeme Ag Prodrugs vom Typ N-hydroxylierter Amidine, Guanidine und/oder Aminohydrazone zur Applikation über die Haut
DE102014108210A1 (de) 2014-06-11 2015-12-17 Dietrich Gulba Rodentizid
EP4070658A1 (de) 2021-04-06 2022-10-12 BIORoxx GmbH Verwendung von blutgerinnungshemmenden verbindungen als rodentizide

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU178398B (en) * 1979-06-12 1982-04-28 Gyogyszerkutato Intezet Process for producing new agmatine derivatives of activity against haemagglutination
US4568636A (en) * 1981-03-25 1986-02-04 Pentapharm Ag Tripeptide derivatives
US4395401A (en) * 1981-09-09 1983-07-26 Smithkline Beckman Corporation Renally active dipeptides
HU192646B (en) * 1984-12-21 1987-06-29 Gyogyszerkutato Intezet Process for preparing new n-alkyl-peptide aldehydes
ZA86746B (en) * 1985-02-04 1986-09-24 Merrell Dow Pharma Novel peptidase inhibitors
DE3505555A1 (de) * 1985-02-18 1986-09-11 Behringwerke Ag, 3550 Marburg Neue oligopeptidylargininolderivate und deren homologe, verfahren zu deren herstellung, deren verwendung und diese enthaltende mittel
PT84170B (pt) * 1986-01-24 1989-03-30 Sanofi Sa Processo para a preparacao de derivados n alfa-substituidos das n alfa-aril-sulfonilaminoacil d-amidinofenil-alaninamidas
DE3606480A1 (de) * 1986-02-28 1987-09-03 Behringwerke Ag Oligopeptidylnitrilderivate, diese enthaltende mittel, verfahren zu ihrer herstellung und ihre verwendung
US5187157A (en) * 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
EP0362002B1 (en) * 1988-09-01 1995-07-26 Merrell Dow Pharmaceuticals Inc. HIV protease inhibitors
ZA897514B (en) * 1988-10-07 1990-06-27 Merrell Dow Pharma Novel peptidase inhibitors
US5273982A (en) * 1990-03-09 1993-12-28 Hoffmann-La Roche Inc. Acetic acid derivatives
US5037819A (en) * 1990-06-04 1991-08-06 Bristol-Myers Squibb Company Azetidin-2-one derivatives as serine protease inhibitors
US5110812A (en) * 1990-06-04 1992-05-05 Bristol-Myers Squibb Co. Azetidin-2-one derivatives as serine protease inhibitors
TW201303B (es) * 1990-07-05 1993-03-01 Hoffmann La Roche
GB9017694D0 (en) * 1990-08-13 1990-09-26 Sandoz Ltd Improvements in or relating to organic chemistry
GB9019558D0 (en) * 1990-09-07 1990-10-24 Szelke Michael Enzyme inhibitors
IL99527A (en) * 1990-09-28 1997-08-14 Lilly Co Eli Tripeptide antithrombotic agents
GB9024129D0 (en) * 1990-11-06 1990-12-19 Thrombosis Research Trust Inhibitors and substrates of thrombin
AU8868991A (en) * 1990-11-15 1992-06-11 Pentapharm Ag Meta-substituted phenyl alanine derivatives
DE4115468A1 (de) * 1991-05-11 1992-11-12 Behringwerke Ag Amidinophenylalaninderivate, verfahren zu deren herstellung, deren verwendung und diese enthaltende mittel als antikoagulantien
CA2075154A1 (en) * 1991-08-06 1993-02-07 Neelakantan Balasubramanian Peptide aldehydes as antithrombotic agents
SE9102462D0 (sv) * 1991-08-28 1991-08-28 Astra Ab New isosteric peptides
CZ333492A3 (en) * 1991-11-12 1993-09-15 Lilly Co Eli Dipeptide of l-azetidine-2-carboxylic acids and l-argininaldehyde, process of its preparation and pharmaceutical preparation in which said dipeptide is comprised
SE9103612D0 (sv) * 1991-12-04 1991-12-04 Astra Ab New peptide derivatives
US5760235A (en) * 1992-03-04 1998-06-02 Gyogyszerkutato Intezet Kft. Anticoagulant peptide derivatives and pharmaceutical compositions containing the same as well as a process for preparation thereof
TW223629B (es) * 1992-03-06 1994-05-11 Hoffmann La Roche
AU675981B2 (en) * 1992-12-02 1997-02-27 Bristol-Myers Squibb Company Guanidinyl-substituted heterocyclic thrombin inhibitors
US5583146A (en) * 1992-12-02 1996-12-10 Bristol-Myers Squibb Company Heterocyclic thrombin inhibitors
SE9301916D0 (sv) * 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
DE4321444A1 (de) * 1993-06-28 1995-01-05 Bernd Prof Dr Clement Pharmazeutische Zubereitung
EP0648780A1 (en) * 1993-08-26 1995-04-19 Bristol-Myers Squibb Company Heterocyclic thrombin inhibitors
TW394760B (en) * 1993-09-07 2000-06-21 Hoffmann La Roche Novel Carboxamides, process for their preparation and pharmaceutical composition containing the same
CA2140598C (en) * 1994-01-27 2010-03-09 Masahiro Ohshima Prolineamide derivatives
US5726159A (en) * 1994-03-04 1998-03-10 Eli Lilly And Company Antithrombotic agents
US5707966A (en) * 1994-03-04 1998-01-13 Eli Lilly And Company Antithrombotic agents
US5705487A (en) * 1994-03-04 1998-01-06 Eli Lilly And Company Antithrombotic agents
ZA951617B (en) * 1994-03-04 1997-02-27 Lilly Co Eli Antithrombotic agents.
US5561146A (en) * 1994-06-10 1996-10-01 Bristol-Myers Squibb Company Modified guanidino and amidino thrombin inhibitors
DE4421052A1 (de) * 1994-06-17 1995-12-21 Basf Ag Neue Thrombininhibitoren, ihre Herstellung und Verwendung
SE504185C2 (sv) * 1994-11-08 1996-12-02 Astra Ab Lagringsstabil vattenlösning för infusion av trombininhibitorer
SE9404196D0 (sv) * 1994-12-02 1994-12-02 Astra Ab New antithrombotic formulation
MX9706069A (es) * 1995-02-17 1997-10-31 Basf Ag Nuevos inhibidores de la trombina.
US5710130A (en) * 1995-02-27 1998-01-20 Eli Lilly And Company Antithrombotic agents
AU698911B2 (en) * 1995-04-04 1998-11-12 Merck & Co., Inc. Thrombin inhibitors
US5629324A (en) * 1995-04-10 1997-05-13 Merck & Co., Inc. Thrombin inhibitors
AR005245A1 (es) * 1995-12-21 1999-04-28 Astrazeneca Ab Prodrogas de inhibidores de trombina, una formulación farmaceutica que las comprende, el uso de dichas prodrogas para la manufactura de un medicamento y un procedimiento para su preparacion

Also Published As

Publication number Publication date
NL300179I2 (nl) 2005-06-01
DE122004000046I1 (de) 2005-04-21
DK0995755T3 (da) 2001-11-12
ES2128283T3 (es) 2005-09-01
DE69614579T2 (de) 2002-06-27
PL187468B1 (pl) 2004-07-30
MY121222A (en) 2006-01-28
CA2238737A1 (en) 1997-07-03
EP1533318A1 (en) 2005-05-25
ES2128283T1 (es) 1999-05-16
DE69634492T2 (de) 2006-04-13
EP0869966B1 (en) 2005-03-16
HK1026214A1 (en) 2000-12-08
DK0869966T3 (da) 2005-06-20
KR19990076624A (ko) 1999-10-15
AU706350B2 (en) 1999-06-17
NZ324902A (en) 2000-06-23
PT995755E (pt) 2002-02-28
US20040162410A1 (en) 2004-08-19
RU2176644C2 (ru) 2001-12-10
BR9612148A (pt) 1999-07-13
NL300179I1 (nl) 2005-05-02
ATE204292T1 (de) 2001-09-15
SK82198A3 (en) 1998-12-02
EE9800187A (et) 1998-12-15
KR100458545B1 (ko) 2005-01-15
US6262028B1 (en) 2001-07-17
ATE291031T1 (de) 2005-04-15
DE69614579D1 (de) 2001-09-20
IS1836B (is) 2002-11-25
JP2000504313A (ja) 2000-04-11
TW541316B (en) 2003-07-11
SI0995755T1 (en) 2002-02-28
WO1997023499A1 (en) 1997-07-03
SI0869966T1 (en) 2005-08-31
NO982809L (no) 1998-08-20
SK285588B6 (sk) 2007-04-05
HK1016610A1 (en) 1999-11-05
NO982809D0 (no) 1998-06-18
EP0995755B1 (en) 2001-08-16
DE122004000046I2 (de) 2011-06-16
NZ504245A (en) 2004-11-26
TR199801151T2 (xx) 1998-08-21
MX9804623A (es) 1998-10-31
HUP9900115A2 (hu) 1999-05-28
IL124857A0 (en) 1999-01-26
US5965692A (en) 1999-10-12
LU91172I2 (fr) 2005-07-11
DE69634492D1 (de) 2005-04-21
HUP9900115A3 (en) 1999-11-29
US20020142968A1 (en) 2002-10-03
IS4756A (is) 1998-05-26
ES2163916T3 (es) 2002-02-01
AU1217897A (en) 1997-07-17
TWI238827B (en) 2005-09-01
PL327569A1 (en) 1998-12-21
EP0995755A1 (en) 2000-04-26
US7354905B2 (en) 2008-04-08
EP0869966A1 (en) 1998-10-14
EE04022B1 (et) 2003-04-15

Similar Documents

Publication Publication Date Title
AR005245A1 (es) Prodrogas de inhibidores de trombina, una formulación farmaceutica que las comprende, el uso de dichas prodrogas para la manufactura de un medicamento y un procedimiento para su preparacion
ES2137998T3 (es) Nuevos derivados de aminoacidos, procedimiento para su preparacion y composiciones farmaceuticas que contienen estos compuestos.
AR024060A1 (es) Nuevos compuestos farmaceuticamente activos
MX9204627A (es) Compuestos 1-acilpiperidina, procedimiento para su preparacion y composicion farmaceutica que los comprende.
AR012593A1 (es) Pirrolopiridinas sustituidas, composicion farmaceutica que las contiene, procedimiento para su preparacion y el uso de las mismas en la manufacturade un medicamento
AR003440A1 (es) Nuevos derivados de aminoacidos, formulacion farmaceutica que los contiene, uso de dichos derivados para preparar medicamentos y procedimiento para la preparacion de dichos derivados.
AR029383A1 (es) Moleculas pequenas, los intermediarios para su sintesis, las composiciones farmaceuticas que las contienen y su uso para preparar un medicamento destinado al tratamiento o la profilaxis de enfermedades inflamatorias o mediadas por celulas inmunes
UY24386A1 (es) Nuevos taxoides, su preparación y composiciones farmacéuticas que los contienen.
MX9302957A (es) Compuestos de xantina, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
AR038818A1 (es) Compuesto de piperidina, uso del mismo para preparar un medicamento, composicion farmaceutica que lo comprende y procedimiento para su preparacion
AR012294A1 (es) Derivados de sulfonamida, un procedimiento para su preparacion, composiciones farmaceuticas que los contienen, uso de dichos derivados para lapreparacion de un medicamento.
GEP20022824B (en) Antipicornaviral Compounds, Pharmaceutical Compositions Containing the Same and Methods for Treatment
DE69725860D1 (de) PLAN ZUR VERABREICHUNG VON H+, K+-ATPase INHIBITOREN
AR032617A1 (es) Utilizacion de derivados de biguanida para fabricar un medicamento que tiene un efecto cicatrizante
AR020688A1 (es) Derivados de la imidazo [4,5-c]-piridin-4-ona, un procedimiento para su preparacion, el empleo de los mismos para preparar un medicamento, los medicamentosa base de estos compuestos, las composiciones farmaceuticas que contienen estos compuestos y un procedimiento para preparar estas composiciones f
BR9911300A (pt) Composto, composição farmacêutica, e, uso do composto
FI932351A (fi) Cyklopeptider och deras anvaendning som resorptionsbefraemjande medel vid applikation pao slemhinnor
TW372969B (en) Pharmaceutical composition for minimizing bone loss
AR029152A1 (es) Benzo[de]isoquinolin-1,3-dionas sustituidas, un procedimiento para prepararlas, las composiciones farmaceuticas que las contienen, un metodo para controlar los trastornos tromboticos que las emplea, un metodo para inducir un efecto antiadhesivo sobre las plaquetas sanguineas empleando las benzo[de]i
AR029001A1 (es) Derivados de bencil-3,4-metilendioxicinamico y el uso de los mismos para la manufactura de un medicamento
AR044869A1 (es) Compuesto de dicetopiperazina, composicion farmaceutica que lo comprende, su uso para fabricar un medicamento y procedimiento para su preparacion
DE69426908D1 (de) Derivate der Phosphonsäure, Verfahren zu ihrer Herstellung und pharmazeutische Zusammensetzungen die sie enthalten
AR009732A1 (es) Bisindolilmaleimidas, proceso para su preparacion, su uso en la preparacion de medicamentos, una composicion farmaceutica que los contiene y compuestosintermediarios para su uso exclusivo en el mencionado proceso
EA200000374A2 (ru) Новые соединения 2,3-метаноаминокислоты, способ их получения и содержащие их фармацевтические композиции
NO20000424D0 (no) Streptograminer, deres fremstilling samt preparater inneholdende forbindelsene

Legal Events

Date Code Title Description
FG Grant, registration